TRDA
Entrada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.13
−0.56%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.98
- Revenue estimate
- $2.1M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$1.01
- EPS estimate
- -$0.97
- Revenue actual
- $898.0K
- Revenue estimate
- $2.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -4.0%
- Revenue beats (12Q)
- 3
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026